Featured Research

from universities, journals, and other organizations

Hope for developing better heart medications

November 18, 2013
University of Utah Health Sciences
Isoforms of PDE3A enzyme might make targets for drugs that prevent sudden cardiac death while still helping the heart pump blood.

Drugs known as PDE3 inhibitors save many lives by helping failing hearts do a better job of pumping blood. But those same medications come with a sometimes deadly cost when taken for long periods: an increased risk for sudden cardiac death.

The drugs work by inhibiting PDE3A, an enzyme that regulates how the heart pumps blood. When PDE3A is inhibited, the heart contracts more forcefully, pumping more blood.

Developing a medication that has the benefits of current drugs but doesn't increase the risk for sudden cardiac death associated has eluded researchers. But an international collaboration led by two Utah researchers is a key first step in finding out whether such a drug may one day be developed.

The research, funded by the Department of Veterans Affairs, was published in the Proceedings of the National Academy of Sciences (PNAS) online the week of Nov. 18, 2013. Matthew A. Movsesian, M.D., professor of medicine at the University of Utah School of Medicine and a cardiologist at the George E. Wahlen Department of Veterans Affairs Medical Center in Salt Lake City, is the senior author. Fabrice Vandeput, Ph.D., a postdoctoral fellow in cardiology at the University of Utah and the VA Medical Center, is first author.

PDE3A comes in three types, or isoforms. PDE3A inhibitors work by inhibiting all three isoforms of the enzyme. Working with colleagues from the United States and Scotland, Vandeput and Movsesian made an important discovery: two of those isoforms, PDE3A1 and PDE3A2, are regulated individually and interact with different proteins in a cell.

"If those isoforms are regulated differently, this tells us they probably are doing different things in cells. And if they interact with different proteins, this means there are molecules that bind to one isoform and not the other," Movsesian says.

That could make it possible to develop a drug that targets one or other of the isoforms to inhibit PDE3A without upping the risk of sudden cardiac death. Years of work must be done before such a drug could be developed and available to heart failure patients. Researchers need to learn much more about the isoforms to understand their roles in how the heart contracts to pump blood (called contractility). They also need to know whether either form of PDE3A contributes to sudden cardiac death in those taking current drugs.

It's also possible that research could determine neither of the isoforms would be a good target for drugs, according to Movsesian, also a professor of pharmacology and toxicology.

"We don't know for certain if these isoforms will ultimately prove to be good targets for drugs," he says. "But we now have reason to believe we could target one or the other."

About 5.7 million people in the United States have heart failure, according to the Centers for Disease Control and Prevention (CDC), with more than 55,000 deaths directly attributed to the condition annually. In 2008, heart failure was a contributing cause in 280,000 deaths, according to the CDC.

PDE3 inhibitors can be taken for shorter periods, when someone has a heart attack and needs help recovering, for example, or for a year or more, such as when a patient with heart failure waits for a transplant or can't survive without the drug. In patients who take them for longer periods, an increase in the mortality rate from sudden cardiac death may outweigh the benefits of increasing cardiac contractility, according to Movsesian.

Story Source:

The above story is based on materials provided by University of Utah Health Sciences. Note: Materials may be edited for content and length.

Journal Reference:

  1. F. Vandeput, N. Szabo-Fresnais, F. Ahmad, C. Kho, A. Lee, J. Krall, A. Dunlop, M. W. Hazel, J. A. Wohlschlegel, R. J. Hajjar, M. D. Houslay, V. C. Manganiello, M. A. Movsesian. Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms. Proceedings of the National Academy of Sciences, 2013; DOI: 10.1073/pnas.1305427110

Cite This Page:

University of Utah Health Sciences. "Hope for developing better heart medications." ScienceDaily. ScienceDaily, 18 November 2013. <www.sciencedaily.com/releases/2013/11/131118152943.htm>.
University of Utah Health Sciences. (2013, November 18). Hope for developing better heart medications. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/11/131118152943.htm
University of Utah Health Sciences. "Hope for developing better heart medications." ScienceDaily. www.sciencedaily.com/releases/2013/11/131118152943.htm (accessed July 22, 2014).

Share This

More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins